zanubrutinib (Brukinsa)
Jump to navigation
Jump to search
Indications
- mantle cell lymphoma
- Waldenstrom's macroglobulinemia[3]
- first line treatment of chronic lymphocytic leukemia & small lymphocytic lymphoma in older patients (> 65 years)[4]
Dosage
Capsule: 80 mg
Pharmacokinetics
- metabolized by CYP3A
- eliminated in feces (38% unchanged) & 8% in urine (< 1% unchanged)
Adverse effects
- leukopenia, neutropenia, thrombocytopenia, anemia
- rash, bruising, diarrhea, cough
- serious: pneumonia (11%), hemorrhage (5%)
Drug interactions
Mechanism of action
- selective Bruton tyrosine kinase inhibitor[4]
More general terms
References
- ↑ RxNorm
- ↑ FDA Drug Approval, Nov 14, 2019 FDA grants accelerated approval to zanubrutinib for mantle cell lymphoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-zanubrutinib-mantle-cell-lymphoma
- ↑ 3.0 3.1 FDA Drug Approval. Aug 31, 2021 FDA approves zanubrutinib for Waldenstrom's macroglobulinemia. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-waldenstroms-macroglobulinemia
- ↑ 4.0 4.1 4.2 Bassett M Zanubrutinib Wins in First-Line CLL for Older Patients. The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial. MedPage Today July 8, 2022 https://www.medpagetoday.com/hematologyoncology/leukemia/99653
Tam CS, Brown JR, Kahl BS et al Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncology. 2022. July 7. PMID: https://www.ncbi.nlm.nih.gov/pubmed/35810754 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00293-5/fulltext - ↑ Highlights of Prescribing Information. BRUKINSA (zanubrutinib) capsules, for oral use https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/213217s000lbl.pdf